These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20352617)

  • 1. Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat.
    Fitzsimons HL; Riban V; Bland RJ; Wendelken JL; Sapan CV; During MJ
    J Gene Med; 2010 Apr; 12(4):385-98. PubMed ID: 20352617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
    Kaplitt MG; Feigin A; Tang C; Fitzsimons HL; Mattis P; Lawlor PA; Bland RJ; Young D; Strybing K; Eidelberg D; During MJ
    Lancet; 2007 Jun; 369(9579):2097-105. PubMed ID: 17586305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.
    LeWitt PA; Rezai AR; Leehey MA; Ojemann SG; Flaherty AW; Eskandar EN; Kostyk SK; Thomas K; Sarkar A; Siddiqui MS; Tatter SB; Schwalb JM; Poston KL; Henderson JM; Kurlan RM; Richard IH; Van Meter L; Sapan CV; During MJ; Kaplitt MG; Feigin A
    Lancet Neurol; 2011 Apr; 10(4):309-19. PubMed ID: 21419704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
    Cunningham J; Pivirotto P; Bringas J; Suzuki B; Vijay S; Sanftner L; Kitamura M; Chan C; Bankiewicz KS
    Mol Ther; 2008 Jul; 16(7):1267-75. PubMed ID: 18523450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of a randomized AAV2-
    Niethammer M; Tang CC; LeWitt PA; Rezai AR; Leehey MA; Ojemann SG; Flaherty AW; Eskandar EN; Kostyk SK; Sarkar A; Siddiqui MS; Tatter SB; Schwalb JM; Poston KL; Henderson JM; Kurlan RM; Richard IH; Sapan CV; Eidelberg D; During MJ; Kaplitt MG; Feigin A
    JCI Insight; 2017 Apr; 2(7):e90133. PubMed ID: 28405611
    [No Abstract]   [Full Text] [Related]  

  • 8. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease.
    Diaz-Nido J
    Curr Opin Investig Drugs; 2010 Jul; 11(7):813-22. PubMed ID: 20571977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.
    Hackett NR; Redmond DE; Sondhi D; Giannaris EL; Vassallo E; Stratton J; Qiu J; Kaminsky SM; Lesser ML; Fisch GS; Rouselle SD; Crystal RG
    Hum Gene Ther; 2005 Dec; 16(12):1484-503. PubMed ID: 16390279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.
    Emborg ME; Carbon M; Holden JE; During MJ; Ma Y; Tang C; Moirano J; Fitzsimons H; Roitberg BZ; Tuccar E; Roberts A; Kaplitt MG; Eidelberg D
    J Cereb Blood Flow Metab; 2007 Mar; 27(3):501-9. PubMed ID: 16835631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.
    Dodiya HB; Bjorklund T; Stansell J; Mandel RJ; Kirik D; Kordower JH
    Mol Ther; 2010 Mar; 18(3):579-87. PubMed ID: 19773746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid α-glucosidase.
    Conlon TJ; Erger K; Porvasnik S; Cossette T; Roberts C; Combee L; Islam S; Kelley J; Cloutier D; Clément N; Abernathy CR; Byrne BJ
    Hum Gene Ther Clin Dev; 2013 Sep; 24(3):127-33. PubMed ID: 24021025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of administration route on the biodistribution and shedding of replication-deficient AAV2: a qualitative modelling approach.
    Brandon EF; Hermsen HP; van Eijkeren JC; Tiesjema B
    Curr Gene Ther; 2010 Apr; 10(2):91-106. PubMed ID: 20222862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease.
    Johnston LC; Su X; Maguire-Zeiss K; Horovitz K; Ankoudinova I; Guschin D; Hadaczek P; Federoff HJ; Bankiewicz K; Forsayeth J
    Mol Ther; 2008 Aug; 16(8):1392-9. PubMed ID: 18545225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys.
    Mori S; Takeuchi T; Enomoto Y; Kondo K; Sato K; Ono F; Iwata N; Sata T; Kanda T
    Jpn J Infect Dis; 2006 Oct; 59(5):285-93. PubMed ID: 17060693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focused ultrasound as a novel strategy for noninvasive gene delivery to retinal Müller glia.
    Touahri Y; Dixit R; Kofoed RH; Miloska K; Park E; Raeisossadati R; Markham-Coultes K; David LA; Rijal H; Zhao J; Lynch M; Hynynen K; Aubert I; Schuurmans C
    Theranostics; 2020; 10(7):2982-2999. PubMed ID: 32194850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.
    Feigin A; Kaplitt MG; Tang C; Lin T; Mattis P; Dhawan V; During MJ; Eidelberg D
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19559-64. PubMed ID: 18042721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
    Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
    Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.
    Sanftner LM; Sommer JM; Suzuki BM; Smith PH; Vijay S; Vargas JA; Forsayeth JR; Cunningham J; Bankiewicz KS; Kao H; Bernal J; Pierce GF; Johnson KW
    Exp Neurol; 2005 Aug; 194(2):476-83. PubMed ID: 16022872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
    Marks WJ; Bartus RT; Siffert J; Davis CS; Lozano A; Boulis N; Vitek J; Stacy M; Turner D; Verhagen L; Bakay R; Watts R; Guthrie B; Jankovic J; Simpson R; Tagliati M; Alterman R; Stern M; Baltuch G; Starr PA; Larson PS; Ostrem JL; Nutt J; Kieburtz K; Kordower JH; Olanow CW
    Lancet Neurol; 2010 Dec; 9(12):1164-1172. PubMed ID: 20970382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.